Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

NRX-1074 in Early Course Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02603458
Recruitment Status : Withdrawn (The study was withdrawn by the sponsor.)
First Posted : November 11, 2015
Last Update Posted : February 5, 2016
Sponsor:
Collaborator:
Naurex, Inc, an affiliate of Allergan plc
Information provided by (Responsible Party):
NYU Langone Health

Brief Summary:
This study seeks to examine the effectiveness of NRX-1074 in the treatment of negative symptoms and cognition in schizophrenia compared to other agents at the glycine site which have demonstrated inconsistent results for negative symptoms. In addition to testing efficacy, we will examine the time course of response of symptoms as well as any effects on memory consolidation.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: NRX-1074 Drug: Placebo Phase 2

Detailed Description:

Investigators propose to conduct a 4-week, randomized, double-blind, placebo-controlled trial in which NRX-1074 will be intravenously administered twice. Subjects will be 62 stable patients ages 18-50 within five years of onset of schizophrenia, treated with any antipsychotic except clozapine at an adequate, stable dose for at least 8 weeks. This study will be conducted by the Schizophrenia Program of the NYU Langone Medical Center and at the Psychiatry Outpatient Clinic of Bellevue Hospital located in New York, NY.

Upon signing consent, patients will undergo screening procedures to assess eligibility. A diagnosis of schizophrenia or schizophreniform disorder will be determined by the Structured Clinical Interview for DSM IV (SCID) completed by a research clinician using all available clinical data and will be confirmed by consensus diagnosis. A comprehensive medical review and physical exam, including routine laboratory tests, will be completed to identify unstable medical illness. A urine toxicology screen and, in females, a pregnancy test will also be performed. A research assistant will complete the Logical Memory Test portion of the Weschler Memory Scale-III (WMS-III).

Subjects who meet study eligibility criteria will complete the baseline visit which will include a one minute infusion of NRX-1074 and the following clinical assessments: Brief Psychiatric Rating Scale (BPRS), Clinical Assessment Interview for Negative Symptoms (CAINS), Calgary Depression Scale for Schizophrenia (CDSS), InterSePT Scale for Suicidal Thinking (ISST), Clinical Global Impression (CGI), and Systematic Assessment for Treatment Emergent Events (SAFTEE). The BPRS, SAFTEE, and ISST will be conducted twice, both before and after the infusion. The remaining assessments will be conducted before the infusion. A cognitive assessment, the Logical Memory Test of the WMS-III, will also be conducted after the infusion.

Patients will return for a visit one day after their baseline infusion, where the BPRS, ISST, CGI, and Logical Memory Test will be conducted. Their next visit will be one week later, where they receive their second NRX-1074 infusion, and will be similar in format to the first baseline infusion with the exception of CAINS and CDSS. One day after the second infusion, patients will be administered the BPRS, CAINS, CDSS, ISST, CGI, and MATRICS Consensus Cognitive Battery (MCCB). Patients will then return weekly for three weeks until Day 28.

The BPRS and ISST will be conducted during the Baseline, Day 1, Day 7, Day 8, Day 14, Day 21, and Day 28 visits. The CGI will be administered during Baseline, Day 1, Day 7, Day 8, Day 14, and Day 28. The CAINS and CDSS will be administered at Baseline, Day 8, Day 14, and Day 28. The SAFTEE will be conducted on Baseline, Day 7, Day 14, Day 21, and Day 28. The Logical Memory Test will be administered during Screening Visit 1, Screening Visit 2, Baseline, and Day 1. The MATRICS will be conducted on Day 8 and Day 28.

The primary outcome measure is the change in BPRS total score from Baseline to 24 hours post infusion on Day 8. Secondary outcome measures include the positive and negative symptom subscales on the BPRS, the CAINS total score, the composite score on the MATRICS 24 hours after the second infusion and the Logical Memory Test compared to placebo one hour after the first infusion (Baseline).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Placebo-controlled Two-dose Trial of NRX-1074 Early in the Course of Schizophrenia
Estimated Primary Completion Date : August 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Placebo Comparator: Placebo
Group of enrolled subjects receiving two infusions of intravenous placebo (5% glucose solution)
Drug: Placebo
Patients will receive two IV placebo infusions 1 week apart, each lasting 1 minute.
Other Name: Sugar IV solution

Experimental: NRX-1074 Dose Group
Group of enrolled subjects receiving two infusions of intravenous NRX-1074 (10 mg)
Drug: NRX-1074
Participants will receive two IV NRX-1074 infusions 1 week apart, each lasting 1 minute.




Primary Outcome Measures :
  1. Brief Psychiatric Rating Scale (BPRS) total score [ Time Frame: Day 8 ]

Secondary Outcome Measures :
  1. Change in total score of Brief Psychiatric Rating Scale (BPRS) from baseline to Day 28 [ Time Frame: Baseline to Day 28 ]
    At each time point (Day 1, Day 7, Day 8, Day 14, Day 21), contrasts between GLYX-13 and placebo will be obtained. The overall contrasts for combined GLYX-13 dose group against placebo were also estimated and tested at each time point.

  2. Change in total score of Clinical Assessment Interview for Negative Symptoms (CAINS) from baseline to day 28 [ Time Frame: Baseline to Day 28 ]
    At each time point (Day 8, Day 14), contrasts between GLYX-13 and placebo will be obtained. The overall contrasts for combined GLYX-13 dose group against placebo were also estimated and tested at each time point.

  3. Total score of MATRICS Consensus Cognitive Battery [ Time Frame: Day 8 ]
  4. Total score of MATRICS Consensus Cognitive Battery [ Time Frame: Day 28 ]
  5. Logical Memory Test of the Wechsler Memory Scale III [ Time Frame: At Screening ]
  6. Logical Memory Test of the Wechsler Memory Scale III [ Time Frame: Baseline ]
  7. Logical Memory Test of the Wechsler Memory Scale III [ Time Frame: Day 1 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18-50
  • Diagnosis of Schizophrenia, Schizophreniform, or schizoaffective disorder as per DSM-V criteria
  • Within five years of onset of illness
  • Treated with any antipsychotic agent except clozapine at an adequate, stable dose for at least 8 weeks.
  • A score of at least 4 (moderate) on at least one BPRS negative symptom item.

Exclusion Criteria:

  • Serious or unstable medical illness
  • Pregnant or nursing
  • Abuse of substances except nicotine in the previous 6 weeks (excluding cannabis use)
  • Positive urine toxicology at screening
  • Experiencing serious suicidal or homicidal ideation within six months
  • Treatment with clozapine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02603458


Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, New York
New York University Langone Medical Center/ Bellevue Hospital
New York, New York, United States, 10016
Sponsors and Collaborators
NYU Langone Health
Naurex, Inc, an affiliate of Allergan plc
Investigators
Layout table for investigator information
Principal Investigator: Donald C Goff, MD NYU Langone Health

Layout table for additonal information
Responsible Party: NYU Langone Health
ClinicalTrials.gov Identifier: NCT02603458     History of Changes
Other Study ID Numbers: S14-01975
First Posted: November 11, 2015    Key Record Dates
Last Update Posted: February 5, 2016
Last Verified: February 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: The study has been withdrawn by the sponsor, so the plan to share data has not been discussed and is undecided.
Keywords provided by NYU Langone Health:
Schizophrenia
Naurex
Intravenous Treatment
NRX-1074
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders